Today’s expectations
Are your treatment expectations in ITP being driven by compromise?
When corticosteroid treatment is no longer sufficient or suitable for patients with ITP, TPO-RAs are recommended for long-term platelet control1–2 – but treatment decisions often involve making compromises.3-9
Treatment failure, lack of sustained efficacy or inadequate platelet control may compromise treatment goals3
Subcutaneous administration may require regular clinic visits and go against patient preference for oral treatment7-9
When it comes to TPO-RA selection,
what matters most to your patients?
Explore what Doptelet can offer
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo aninvasive procedure. 10
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). 10
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
References
1.Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020 Jan 28;4(2):252]. Blood Adv. 2019;3(23):3829-3866. 2. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. 3. Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018;93(1):58-64. 4. Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313-321. Published 2019 Sep 5. 5.Tsykunova G, Ghanima W. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives. Ther Clin Risk Manag. 2022;18:273-286. Published 2022 Mar 24. 6. Revolade Summary of Product Characteristics. 05/2023. 7. Kuter DJ, Arnold DM, Rodeghiero F, et al. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020;95(6):643-651. 8. McDonald V, Newland A, Morgan M, et al. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). Hematology. 2021;26(1):799-808. 9. Nplate Summary of Product Characteristics. 10/2022. 10. Doptelet Summary of Product Characteristics. 22/05/2025